



Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

November 1, 2018

MONROVIA, Calif., Nov. 1, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) will be presented in an oral session at the 2018 American Society of Hematology (ASH) Annual Meeting on Monday, December 3, 2018.

Key Highlights from the Abstract

- At data cut off on June 27, 2018, 63 patients with relapsed/refractory AML and one patient with B cell acute lymphoblastic leukemia had received XmAb®14045. Patients had a median age of 61 years and were heavily pretreated, having a median of three prior therapies, and 30% (n=19/64) had undergone prior allogeneic stem cell transplantation.
- No MTD was identified, and cytokine release syndrome (CRS) was the most common toxicity occurring in 49 of 64 patients (77%). Seven patients (11%) experienced Grade 3 or 4 CRS. CRS was generally manageable with premedication.
- 23% of evaluable patients with AML achieved either complete remission (CR) or CR with incomplete hematologic recovery (CRi) at the two highest dose levels studied to date (1.3 and 2.3 mcg/kg weekly; n=3/13).
- Two patients with responses were bridged to stem cell transplantation, and the third was ineligible but remained in remission at 14+ weeks after initiating therapy.

"Initial results from the ongoing study of our lead bispecific antibody XmAb14045 in heavily pretreated patients with acute myeloid leukemia demonstrate that several patients achieved complete remissions," said Paul Foster, M.D., senior vice president and chief medical officer at Xencor. "XmAb14045 is a full-length immunoglobulin designed to be dosed intermittently. We continue to optimize dosing regimen as we advance the Phase 1 study."

Presentation Details

- Abstract: 763
- Title: Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb®14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
- Presenter: Farhad Ravandi, M.D., Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M.D. Anderson Cancer Center
- Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Treatment Strategies
- Date & Time: Monday, December 3, 2018, 2:45 p.m. PST
- Location: Manchester Grand Hyatt San Diego, Seaport Ballroom F

The accepted abstract is now available on the [ASH conference website](#).

Analyst & Investor Event and Webcast Information

Xencor will host an analyst and investor event on Monday, December 3, 2018 from 8:00 to 10:00 p.m. PST with formal remarks at 8:30 p.m. PST. The event will feature a discussion of the data presented at ASH and Xencor's bispecific oncology pipeline. The event will be webcast live and can be accessed under Events & Presentations in the Investors section of www.xencor.com, where it will be archived for 30 days.

About XmAb®14045

XmAb14045 is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb® Bispecific Fc domain

serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on XmAb14045. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by XmAb14045 activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 12 candidates engineered with Xencor's XmAb[®] technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb[®]5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb[®]7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb[®]14045 in Phase 1 development for acute myeloid leukemia; XmAb[®]13676 in Phase 1 development for B-cell malignancies; XmAb[®]18087 in Phase 1 development for the treatment of neuroendocrine tumors and gastrointestinal stromal tumors; XmAb[®]20717 in Phase 1 development for the treatment of advanced solid tumors, and XmAb[®]22841, XmAb[®]23104 and XmAb[®]24306 in pre-clinical development for the treatment of multiple cancers. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, CSL, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, the quotations from Xencor's president and chief executive officer and any expectations relating to Xencor's financial expectations and business, the timing and success of clinical trials, future product candidates, Xencor's research and development programs, partnering efforts and capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2017 as well as Xencor's subsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.



[View original content to download multimedia: http://www.prnewswire.com/news-releases/xencor-to-present-initial-data-from-phase-1-study-of-xmab14045-bispecific-antibody-in-acute-myeloid-leukemia-at-the-2018-ash-annual-meeting-300741845.html](http://www.prnewswire.com/news-releases/xencor-to-present-initial-data-from-phase-1-study-of-xmab14045-bispecific-antibody-in-acute-myeloid-leukemia-at-the-2018-ash-annual-meeting-300741845.html)

SOURCE Xencor, Inc.

Investor Contact: John Kuch, Senior Vice President, Finance and Chief Financial Officer, Xencor, Tel: 626-737-8013, jkuch@xencor.com; Corporate Communications Contact: Jason I. Spark, Canale Communications for Xencor, Tel: 619-849-6005, jason@canalecomm.com